Last reviewed · How we verify
Drug: carboplatin
Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.
Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription. Used for Ovarian cancer, Breast cancer, Lung cancer.
At a glance
| Generic name | Drug: carboplatin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carboplatin works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Approved indications
- Ovarian cancer
- Breast cancer
- Lung cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neuropathy
Key clinical trials
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: carboplatin CI brief — competitive landscape report
- Drug: carboplatin updates RSS · CI watch RSS
- AstraZeneca portfolio CI